🔗 Share this article The Global Health Body Raises Concern Over Acute Shortage of Obesity Injections Fewer than one in 10 individuals who could benefit from obesity jabs including Wegovy have access to them, warns the WHO as it issues its first guidance on the drugs. Considering over a billion individuals worldwide currently obese, it is calling for increased and just availability to this class of drugs. According to estimates, more than two billion are projected to be living with obesity by 2030 unless action is taken. "Our latest guidelines affirms that obesity is a chronic disease that can be treated with comprehensive and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and supply-chain constraints are significant barriers to widespread access to the jabs that can help people shift substantial body mass, explains the body. Weight-Loss Drug Supply Crisis Even under the present most favorable outlook, the manufacturing of these medications would only suffice for about 100 million people – fewer than 10% of the global need, as stated by the health organization. The guideline calls on governments and firms to increase availability, by strategies including voluntary licensing. The intellectual property rights on a key compound – the main ingredient of a leading brand – is due to expire in multiple nations in 2026. The Way Obesity Jabs Function GLP-1 drugs replicate a biological compound to slow digestion, suppress the appetite and enhance feelings of fullness so people consume fewer calories. Individuals usually begin shedding pounds in the initial weeks of beginning the weekly injections. Research suggests users may regain a significant portion within a year of stopping the drug, as their normal food cravings resume. To be overweight or obese elevates your chance for contracting diseases, like type 2 diabetes, cardiovascular issues, stroke, and some malignancies. Obesity affects individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.
Fewer than one in 10 individuals who could benefit from obesity jabs including Wegovy have access to them, warns the WHO as it issues its first guidance on the drugs. Considering over a billion individuals worldwide currently obese, it is calling for increased and just availability to this class of drugs. According to estimates, more than two billion are projected to be living with obesity by 2030 unless action is taken. "Our latest guidelines affirms that obesity is a chronic disease that can be treated with comprehensive and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and supply-chain constraints are significant barriers to widespread access to the jabs that can help people shift substantial body mass, explains the body. Weight-Loss Drug Supply Crisis Even under the present most favorable outlook, the manufacturing of these medications would only suffice for about 100 million people – fewer than 10% of the global need, as stated by the health organization. The guideline calls on governments and firms to increase availability, by strategies including voluntary licensing. The intellectual property rights on a key compound – the main ingredient of a leading brand – is due to expire in multiple nations in 2026. The Way Obesity Jabs Function GLP-1 drugs replicate a biological compound to slow digestion, suppress the appetite and enhance feelings of fullness so people consume fewer calories. Individuals usually begin shedding pounds in the initial weeks of beginning the weekly injections. Research suggests users may regain a significant portion within a year of stopping the drug, as their normal food cravings resume. To be overweight or obese elevates your chance for contracting diseases, like type 2 diabetes, cardiovascular issues, stroke, and some malignancies. Obesity affects individuals in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, per the health agency.